Societe Generale’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Societe Generale’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$151K	Buy	+8,400	New	+$165K	﹤0.01%	2226

Other funds holding BBC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MFS

MSI Financial Services Springfield, Massachusetts $3.07B AUM 10.22% 1-Year Est. Return

Societe Generale's BBC Position: Q2 2016 in Review

Societe Generale opened a new position in Virtus Biotech Clinical Trials ETF (BBC) in Q2 2016: 8,400 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #2226 among its holdings.

14 funds tracked by Wall St. Rank hold BBC as of Q2 2016.

Societe Generale held 8,400 shares of Virtus Biotech Clinical Trials ETF worth $151K as of Q2 2016.
Virtus Biotech Clinical Trials ETF was a new Societe Generale position in Q2 2016.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2226 holding.
14 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.